Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

Phase 4

Not yet recruiting

Conditions: Cystectomy
Bladder Cancer Requiring Cystectomy
Postoperative Infections
Antibiotic Prophylaxis
Ileal Conduit

Interventions: Drug: Pivmecillinam
Drug: Amoxicillin clavulanic acid
Drug: Amoxicillin
Drug: Cefuroxime
Drug: Ciprofloxacin
Drug: Linezolid
Drug: Nitrofurantoin
Drug: Trimethoprim
Drug: Sulfamethoxazole trimethoprim
Drug: Fluconazole

First Posted Date: 2024-11-29

Last Posted Date: 2024-12-16

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 248

Registration Number: NCT06709196

Locations: 🇩🇰
Department of Urology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Department of Urology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Department of Urology, Rigshospitalet, Copenhagen, Denmark

and more 2 locations

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

Phase 4

Recruiting

Conditions: Cat Bite
Anti-bacterial Agents
Hand Injuries
Arm Injury
Infection, Bacterial

Interventions: Drug: Amoxicillin/clavulanate
Other: Placebo (microcrystalline cellulose)
Procedure: Wound management
Drug: Ciprofloxacin
Drug: Clindamycin

First Posted Date: 2023-05-06

Last Posted Date: 2024-10-01

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 72

Registration Number: NCT05846399

Locations: 🇺🇸
University of Missouri, Columbia, Missouri, United States

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: SAR441566
Drug: Ciprofloxacin

First Posted Date: 2023-05-06

Last Posted Date: 2024-01-18

Lead Sponsor: Sanofi

Target Recruit Count: 60

Registration Number: NCT05844735

Locations: 🇺🇸
TKL Research, Inc. Site Number : 8400001, Fair Lawn, New Jersey, United States

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Not Applicable

Completed

Conditions: Upper Respiratory Tract Infections

Interventions: Drug: 0.9% NaCl physiological saline Nasal-spraying
Combination Product: LiveSpo Navax®
Drug: Augmentin 500Mg Tablet
Drug: Acetylcysteine
Drug: Xylometazoline Nasal
Drug: Cefotaxime
Drug: Ciprofloxacin

First Posted Date: 2023-04-07

Last Posted Date: 2024-08-22

Lead Sponsor: Anabio R&D

Target Recruit Count: 175

Registration Number: NCT05804123

Locations: 🇻🇳
Thai Binh University of Medicine and Pharmacy, Thai Binh Medical University Hospital and Thai Binh Children's Hospital, Thai Binh, Vietnam

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Procedure: Biopsy
Drug: FOLFIRINOX
Drug: Ciprofloxacin
Drug: Metronidazole
Drug: Pembrolizumab
Procedure: Surgical Resection

First Posted Date: 2022-07-18

Last Posted Date: 2024-10-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 25

Registration Number: NCT05462496

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Modified Surface of PLGA Nanoparticles in Smart Hydrogel

Early Phase 1

Completed

Conditions: Antibiotic Resistant Infection

Interventions: Drug: Ciprofloxacin

First Posted Date: 2022-07-05

Last Posted Date: 2022-07-05

Lead Sponsor: British University In Egypt

Target Recruit Count: 55

Registration Number: NCT05442736

Locations: 🇪🇬
Mona Arafa, Cairo, Egypt

Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma

Phase 1

Conditions: Rhinoscleroma

Interventions: Drug: Doxycycline
Drug: Rifampin
Drug: Ciprofloxacin

First Posted Date: 2022-06-24

Last Posted Date: 2022-07-07

Lead Sponsor: Assiut University

Target Recruit Count: 45

Registration Number: NCT05431673

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Phase 2

Recruiting

Conditions: Gonorrhea Male

Interventions: Drug: Cefixime
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA1090
Biological: Meningococcal Group B Vaccine
Biological: Influenza Vaccine
Biological: Tetanus-diptheria Vaccine

First Posted Date: 2022-03-24

Last Posted Date: 2023-05-24

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 140

Registration Number: NCT05294588

Locations: 🇺🇸
Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina, United States